T-Therapeutics raises $133M to take TCR bispecifics into the clinic
Cambridge biotech T-Therapeutics has closed an oversubscribed $133 million Series B to push its first two drugs into human trials. The round, announced on November 5, was co-led by Advent Life Sciences and the British Business Bank. New investors include Eli Lilly, Johnson & Johnson Innovation (JJDC), Samsara BioCapital and M-Ventures.
It is one of the largest private rounds for a UK biotech this year. It also comes barely a year after the company finished its Series A. That round reached $91 million in November 2025, when Tencent and BGF joined a $32 million extension.
Going from a $91 million Series A to a $133 million Series B before a single patient has been dosed says a lot about how investors view the science.
What T-Therapeutics actually makes
The company builds T-cell engagers: bispecific molecules with two arms. One arm grabs a target on a diseased cell. The other grabs CD3, a protein on the surface of T cells. The molecule acts like a bridge, pulling an immune cell right up against the cell it should kill.
T-cell engagers are not new. Several are approved for blood cancers. Most of them, though, use antibody fragments to find their targets, and antibodies can only see proteins sitting on the outside of a cell. That rules out a huge share of the proteins that actually drive cancer, which live inside the cell.
T-Therapeutics' twist is to use T-cell receptors (TCRs) as the targeting arm instead. TCRs are the immune system's own recognition tool. They read small fragments of internal proteins that cells display on their surface through HLA molecules. In practice, that opens up targets that were previously considered "undruggable."
The company generates these receptors with its proprietary OpTiMus platform. According to Cambridge Enterprise, OpTiMus produces fully human TCRs, which should lower the risk of the body reacting against the drug itself. Those TCRs are then paired with the company's own next-generation CD3 engagers.
Two programmes, two very different diseases
The new money funds clinical proof-of-concept for two lead candidates, both TCR-CD3 bispecifics.
Oncology. The lead cancer programme goes after what the company calls a pan-tumour driver target, with potential across several solid tumour types. Solid tumours are where T-cell engagers have struggled most. Advent partner Dominic Schmidt told Pharmaceutical Technology that a lack of suitable targets has held the field back, and that this platform addresses exactly that problem.
Autoimmunity. The second programme aims for an "immune reset". It would selectively deplete the specific immune cells that drive chronic tissue inflammation, rather than suppressing the whole immune system. That is a big shift from today's standard of care, where many patients take broad immunosuppressants for life.
The company has not disclosed the targets, the specific indications or a trial start date. That is common at this stage, but it means outside observers are taking a lot on trust.
Why big pharma wrote cheques
The investor list is the most telling part of this round. Lilly, JJDC, M-Ventures (Merck KGaA's venture arm) and existing backer Sanofi Ventures all have their own immunology and oncology pipelines.
Strategic investors at Series B often signal future partnership or acquisition interest, and having four of them in one round is unusual.
It fits a wider pattern. Pharma companies have been signing T-cell engager deals across both cancer and autoimmune disease, with BMS, GSK, Gilead, UCB and Boehringer Ingelheim all active recently. Autoimmune use is the newer frontier. Early academic results with T-cell-depleting approaches in lupus and similar diseases have sparked an industry-wide rush, and a GlobalData survey found many biopharma professionals expect T-cell engagers to have their biggest near-term impact in immunology. If you track biotech funding trends, this is the clearest theme of 2026: capital is concentrating in platforms that serve both oncology and immunology at once.
The British Business Bank's co-lead role matters too.
It reflects a UK policy push to keep homegrown life-science companies financed at home, instead of watching them redomicile to the US at Series B. T-Therapeutics is a University of Cambridge spinout, and the round keeps its centre of gravity in the UK.
The proof that matters
There is precedent for TCR-based bispecifics working. Immunocore's Kimmtrak became the first approved TCR therapeutic in 2022, for a rare eye cancer called uveal melanoma. It showed the concept can deliver a real survival benefit. It also showed the limits: one HLA type, one target, one rare indication.
T-Therapeutics has to clear several hurdles to do better:
HLA restriction. TCR drugs only work in patients with a matching HLA type, which can shrink the eligible population.
Safety. T-cell engagers can trigger cytokine release syndrome, and fully human TCRs need to prove they avoid cross-reactivity with healthy tissue.
Solid tumour biology. Getting T cells into dense, immunosuppressive tumours remains hard, whatever the targeting arm.
Autoimmune bar. In chronic disease, the safety bar is higher than in cancer. Patients and regulators will tolerate far less risk.
The company is getting ready for that step. It has appointed Dr Kirsty Crame as Chief Development Officer, with TCR experience from Medigene and Gadeta, and investor representatives from Advent, the British Business Bank, JJDC and Samsara are joining the board.
What to watch
CEO Theodora Harold called the round "a key step in our transition to a clinical-stage company." Over the next 12 to 24 months, the signals that matter are:
First-patient-dosed announcements for both lead programmes.
Disclosure of the oncology target and which tumour types come first.
Early safety data, especially on cytokine release and off-target effects.
Whether any of the four pharma investors moves to a formal partnership.
If the clinical data hold up, T-Therapeutics could become one of the few European biotechs with credible assets in both cancer and autoimmunity. If they don't, $133 million will have bought a very expensive lesson on how hard intracellular targets really are.